Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

E. C. Reed, R. A. Bowden, P. S. Dandliker, K. E. Lilleby, J. D. Meyers

Research output: Contribution to journalArticle

403 Citations (Scopus)

Abstract

Cytomegalovirus is life-threatening in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), recipients of organ allografts, and neonates. The high incidence of cytomegalovirus infection and disease in recipients of bone marrow allograft and the 85% mortality rate associated with cytomegalovirus pneumonia makes this disease the leading infectious cause of death after allogeneic bone marrow transplant. Various animal models suggest the combination of an antiviral agent and passive immunotherapy with antibody is more effective for the treatment of viral infections than either modality alone, including a recent study that combined ganciclovir and anticytomegalovirus antiserum. The severity of cytomegalovirus pneumonia, the poor results obtained with previous regimens, and the lack of other modalities for the treatment of cytomegalovirus infection led us to treat 25 patients with allogeneic marrow transplants and proven cytomegalovirus pneumonia with the combination of ganciclovir and intravenous cytomegalovirus immunoglobulin in a consecutive entry trial.

Original languageEnglish (US)
Pages (from-to)783-788
Number of pages6
JournalAnnals of internal medicine
Volume109
Issue number10
DOIs
StatePublished - Jan 1 1988

Fingerprint

Ganciclovir
Intravenous Immunoglobulins
Cytomegalovirus
Pneumonia
Bone Marrow
Transplants
Cytomegalovirus Infections
Allografts
Therapeutics
Passive Immunization
Immunocompromised Host
Virus Diseases
Antiviral Agents
Communicable Diseases
Immune Sera
Cause of Death
Acquired Immunodeficiency Syndrome
Animal Models
Newborn Infant
Mortality

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. / Reed, E. C.; Bowden, R. A.; Dandliker, P. S.; Lilleby, K. E.; Meyers, J. D.

In: Annals of internal medicine, Vol. 109, No. 10, 01.01.1988, p. 783-788.

Research output: Contribution to journalArticle

@article{aa8c6a886dc540ac8c6e69cc17e84d73,
title = "Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants",
abstract = "Cytomegalovirus is life-threatening in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), recipients of organ allografts, and neonates. The high incidence of cytomegalovirus infection and disease in recipients of bone marrow allograft and the 85{\%} mortality rate associated with cytomegalovirus pneumonia makes this disease the leading infectious cause of death after allogeneic bone marrow transplant. Various animal models suggest the combination of an antiviral agent and passive immunotherapy with antibody is more effective for the treatment of viral infections than either modality alone, including a recent study that combined ganciclovir and anticytomegalovirus antiserum. The severity of cytomegalovirus pneumonia, the poor results obtained with previous regimens, and the lack of other modalities for the treatment of cytomegalovirus infection led us to treat 25 patients with allogeneic marrow transplants and proven cytomegalovirus pneumonia with the combination of ganciclovir and intravenous cytomegalovirus immunoglobulin in a consecutive entry trial.",
author = "Reed, {E. C.} and Bowden, {R. A.} and Dandliker, {P. S.} and Lilleby, {K. E.} and Meyers, {J. D.}",
year = "1988",
month = "1",
day = "1",
doi = "10.7326/0003-4819-109-10-783",
language = "English (US)",
volume = "109",
pages = "783--788",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "10",

}

TY - JOUR

T1 - Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

AU - Reed, E. C.

AU - Bowden, R. A.

AU - Dandliker, P. S.

AU - Lilleby, K. E.

AU - Meyers, J. D.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Cytomegalovirus is life-threatening in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), recipients of organ allografts, and neonates. The high incidence of cytomegalovirus infection and disease in recipients of bone marrow allograft and the 85% mortality rate associated with cytomegalovirus pneumonia makes this disease the leading infectious cause of death after allogeneic bone marrow transplant. Various animal models suggest the combination of an antiviral agent and passive immunotherapy with antibody is more effective for the treatment of viral infections than either modality alone, including a recent study that combined ganciclovir and anticytomegalovirus antiserum. The severity of cytomegalovirus pneumonia, the poor results obtained with previous regimens, and the lack of other modalities for the treatment of cytomegalovirus infection led us to treat 25 patients with allogeneic marrow transplants and proven cytomegalovirus pneumonia with the combination of ganciclovir and intravenous cytomegalovirus immunoglobulin in a consecutive entry trial.

AB - Cytomegalovirus is life-threatening in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), recipients of organ allografts, and neonates. The high incidence of cytomegalovirus infection and disease in recipients of bone marrow allograft and the 85% mortality rate associated with cytomegalovirus pneumonia makes this disease the leading infectious cause of death after allogeneic bone marrow transplant. Various animal models suggest the combination of an antiviral agent and passive immunotherapy with antibody is more effective for the treatment of viral infections than either modality alone, including a recent study that combined ganciclovir and anticytomegalovirus antiserum. The severity of cytomegalovirus pneumonia, the poor results obtained with previous regimens, and the lack of other modalities for the treatment of cytomegalovirus infection led us to treat 25 patients with allogeneic marrow transplants and proven cytomegalovirus pneumonia with the combination of ganciclovir and intravenous cytomegalovirus immunoglobulin in a consecutive entry trial.

UR - http://www.scopus.com/inward/record.url?scp=0024232608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024232608&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-109-10-783

DO - 10.7326/0003-4819-109-10-783

M3 - Article

C2 - 2847610

AN - SCOPUS:0024232608

VL - 109

SP - 783

EP - 788

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 10

ER -